EXHIBIT 10.18
AMENDMENT
This amendment (the "Amendment"), dated March 25, 2003, is being made between
Keryx Biopharmaceuticals, Inc., a corporation organized under the laws of the
State of Delaware, with offices at 000 Xxxxxxxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx
00000 ("Keryx"), and Children's Medical Center Corporation, 000 Xxxxxxxx Xxxxxx,
Xxxxxx, Xxxxxxxxxxxxx 00000 ("CMCC").
WHEREAS the parties executed a License Agreement, dated November 12, 1999,
pursuant to which, among other things, meet certain development milestones (the
"License Agreement"); and
WHEREAS the parties have determined that the proper development and funding of
the technology that is the subject of the License Agreement justifies amendments
to the clauses addressing the development milestones;
IT IS HEREBY AGREED by and between the parties:
1. Article III.B.1 of the License Agreement shall be amended to read as
follows:
B. Licensee shall accomplish development of Licensed Products and/or
Licensed Processes according to the following timetable:
1. file an Initial New Drug Application ("IND") for a
Licensed Product with United States Food and Drug
Administration ("FDA") or its foreign equivalent in a
country with reasonably comparable requirements within
forty eight (48) months from the identification of the
first lead compound; and
2. This Amendment shall not be deemed to alter in any manner any rights
and/or obligations of either party except as specifically set forth
above.
IN WITNESS WHEREOF, the parties hereto have executed this Amendment, by proper
persons duly authorized.
KERYX BIOPHARMACEUTICALS, INC. CHILDRENS MEDICAL CENTER CORPORATION
By: /s/ Xxxxxxx X. Xxxxx By:/s/ Xxxxxx X. Xxxxxxxx
-------------------------- ---------------------------------
Name: Xxxxxxx X. Xxxxx Name: Xxxxxx X. Xxxxxxxx
Title: Chief Executive Officer Title: Chief Intellectual Property
Officer
